Magnesium L-threonate: what research shows about the brain and sleep

Editorial draft. Medical claims and source attributions have not yet been independently checked; clinical sign-off is pending.

What is magnesium L-threonate?

Magnesium L-threonate is a magnesium salt in which one magnesium ion is bound to two molecules of L-threonate. L-threonate is formed when the body metabolizes vitamin C. The compound was developed at MIT and introduced in a 2010 paper in Neuron. Its commercial brand form is called Magtein.

Like glycinate, citrate and malate, L-threonate belongs to the organic magnesium salts. What sets it apart is mainly the hypothesis behind its development: other forms are often used to cover general magnesium needs, while the threonate component was meant to give special support to magnesium delivery into the central nervous system. Whether this targeted advantage actually happens in humans is a separate research question.

Why is the threonate component interesting?

One magnesium ion binds to two molecules of L-threonate. L-threonate is an oxidized metabolite of L-ascorbic acid, in other words vitamin C. The source article describes the complex as neutral and fairly lipophilic and concludes that it may cross the blood-brain barrier more easily. This structural explanation should be read as a hypothesis. Clinically, it is not the same as proven uptake into the brain.

Comparisons between organic and inorganic salts are often about absorption in the gut, for example glycinate versus oxide. With threonate the further question is where the magnesium goes once it has been absorbed. Early rodent data pointed to more intracellular magnesium in the brain. Later mechanistic work examined the relationships at the level of the synapses. Source Source

From the research lab to the supplement

Magnesium L-threonate does not occur in foods in any meaningful amount and is made chemically. It came out of Guosong Liu’s lab at MIT; Inna Slutsky was first author of the foundational paper. The researchers studied whether more magnesium in the brain improves memory and the adaptability of synapses, the contact points between nerve cells. The 2010 Neuron paper became the scientific basis for the product category. Source

The compound was then licensed and marketed as Magtein, first through Magceutics and later through AIDP. A 2016 human study tested a corresponding formulation in older adults with cognitive complaints. The MIT origin, the publications and the trademark rights all play a large part in the marketing. Research and commercial interests are closely linked here, and that should be kept in mind when weighing the studies. Source

How might magnesium L-threonate reach the brain?

The central hypothesis runs like this: magnesium L-threonate taken by mouth raises circulating magnesium, and threonate eases a preferential delivery into the central nervous system. Once there, more intracellular magnesium could support synapse density and NMDA-dependent plasticity. This pathway was first studied in rodents. Further work looked at how threonate influences synapse density through neuronal magnesium concentrations. Source Source

Magnesium in the brain and synapse density

In rodent models, orally administered magnesium L-threonate raised magnesium in cerebrospinal fluid and brain more than other salts did at comparable elemental amounts. This went along with higher synapse density and better spatial memory. One mechanism under discussion involves NMDA receptors: magnesium blocks them in a voltage-dependent way, while intracellular concentrations affect their role in long-term potentiation. More recent mechanistic work describes intracellular magnesium promoting plasticity in the hippocampus. In animal models with Alzheimer’s-like pathology, MgT prevented synapse loss and improved cognitive deficits. These are preclinical results, not a proven Alzheimer’s treatment in humans. Source Source Source

Two findings argue against reading too much into this. A 2025 rat study in a hypothyroidism model found less amyloid-β but no cognitive improvement. A favorable biomarker, in other words, does not necessarily change function. In addition, magnesium acetyl taurate reached higher brain concentrations than MgT in an animal comparison. So a unique advantage of L-threonate has not been established. Source Source

Absorption, half-life and the open question of brain concentration

A systematic review describes organic magnesium salts as a group as more bioavailable than inorganic ones. The source article includes L-threonate in this classification. Plasma magnesium usually rises only moderately with supplementation. Serum levels, however, give an incomplete picture of tissue status; an intracellular deficiency can be present even when values are within the reference range. Above all, serum levels cannot be used to draw direct conclusions about the brain. Source Source Source

The source article cites no human imaging study showing that oral magnesium L-threonate specifically raises magnesium concentration in the brain. Animal work on blood-brain barrier permeability and amyloid-β transport, along with organoid experiments on how tissue responds to magnesium salts, offers mechanistic clues. These do not prove that oral MgT passes into the human brain to a clinically relevant extent. Data on the half-life of the threonate component are sparse. In human studies it was often taken with food; the pharmacokinetics of different dosing times are not well characterized. Source Source

What do the studies on MgT show?

Research has looked at cognition in older adults with complaints, sleep quality, synapse density and Alzheimer’s-related mechanisms, and at whether magnesium actually rises in the human brain.

Cognition in older adults: limited human findings

The 2016 MMFS-01 study randomized 44 adults aged 50–70 with self-reported cognitive complaints and followed them for 12 weeks. The dose was 1.5–2 g/day of Magtein. MMFS-01 also contained low-dose vitamin C and vitamin D3 to limit the influence of any baseline deficiency. A composite cognitive test score improved. The study was small, ran at a single site and was funded by the company that holds the Magtein patent. The source article describes no independent replication. Another RCT from 2025, also industry funded, found improvements in cognition, working memory and reaction time in 18- to 45-year-olds who were dissatisfied with their sleep. These are preliminary positive signals for specific groups, not an established cognitive therapy. Source Source

Sleep and daytime well-being: limited human findings

A 2024 RCT compared Magtein with placebo in about 80 adults with sleep complaints. The Magtein group reported improvements in subjective sleep quality, mood, energy and daytime functioning. The limitations are industry funding, subjective endpoints and the lack of polysomnography to confirm changes in sleep architecture. Reviews of magnesium supplementation in general find inconsistent associations; benefits seem more likely when magnesium status is low. The MgT findings justify further research and need independent confirmation. Source Source Source

Synapses and Alzheimer’s-related pathology: animal data

Papers from 2010, 2014 and 2018, two studies from 2025 and one further paper from 2025 report effects on synapse density, amyloid pathology or neuroinflammation in rodent models. These mechanistic findings have been repeated, but whether they carry over to humans is an open question. The 2025 hypothyroid rat model, with less amyloid-β and no cognitive improvement, shows the limits of such biomarker results. MgT is therefore not an established strategy for treating or preventing Alzheimer’s disease. Source Source Source Source Source Source

More magnesium in the human brain: not yet confirmed

Rodent studies from 2010 and 2016 showed higher magnesium concentrations in cerebrospinal fluid and brain after oral MgT. According to the source article, corresponding imaging evidence in humans is lacking. In an animal comparison, acetyl taurate reached higher concentrations than MgT. The hypothesis of better delivery to the brain remains mechanistically plausible and is supported by animal data, but it has not been confirmed in humans; any advantage over other forms is also an open question. Source Source Source

Effects that have not been demonstrated so far:

• Treating, preventing or reversing Alzheimer’s disease or other cognitive disorders.

• An increase in brain magnesium confirmed by human imaging.

• Replacing medically indicated treatment of sleep disorders, depression or anxiety disorders.

• A reliable advantage over other magnesium salts on clinical endpoints in humans. The cognition and sleep findings described here do not amount to a general confirmation of superiority either.

How do the forms of magnesium differ?

Magnesium supplements differ in absorption, elemental content and intended use. The source article cites differences of roughly 5- to 10-fold between oxide and well-absorbed organic salts; this blanket range depends on the method used and needs checking. L-threonate is marketed especially for targeted delivery to the central nervous system (CNS). For general shortfalls in supply, the source article describes glycinate and citrate as options with a longer track record.

• L-threonate, or Magtein: about 144 mg of elemental magnesium per 2 g of Magtein. The source article also gives 1–2 g per capsule; this product detail needs separate checking. The development rationale concerns delivery to the CNS, while plasma magnesium rises only moderately. For any product, check that it matches the branded raw material that was studied, using a COA (certificate of analysis) and traceable sourcing. A generic product is not identical to a studied formulation just because it carries the same name. Source

• Magnesium bisglycinate: bound to glycine, about 14% elemental magnesium by weight. The source article gives 200–400 mg of elemental magnesium per capsule and calls it particularly well studied for subjective sleep and anxiety complaints. Both claims need checking against the specific product or study. What matters is a clear declaration as bisglycinate rather than an opaque mix of oxide and glycine.

• Magnesium citrate: about 16% elemental magnesium; the source article cites a common 200–400 mg elemental. It is well absorbed and has long been used for general supplementation and as a laxative. A verifiable quality claim, such as USP grade, can help when judging a product.

• Magnesium oxide: about 60% magnesium by mass, but according to the source article only about 4% bioavailability. It is found in many multivitamins and is used as a laxative. The low absorption limits its suitability for general repletion or for any CNS promises derived from it; the exact percentage is not a universal product property. Source

Programs such as USP, NSF International and ConsumerLab check, depending on the program, label accuracy, contaminants and dissolution. For Magtein, the supply chain back to the licensed ingredient should be traceable. A COA can confirm the specific salt form. The brand name alone, however, is no substitute for independent testing of quality or efficacy. Which form fits depends on absorption, tolerability and the question being asked. Source

US regulatory information from the source article, as of May 2026

In the United States, magnesium L-threonate is sold as a dietary supplement under DSHEA. The source article cites no FDA approval for a medical indication and no FDA-authorized health claim related to cognition, sleep or neurological disease. It attributes the Magtein brand to Magceutics and distribution to AIDP; the research line goes back to MIT. This information should not be read as a verified current regulatory status in Germany.

The source article mentions FTC attention to advertising for cognitive supplements, but cites no documented pattern of warning letters specific to this compound. This regulatory assessment still needs to be verified. Likewise, the statement that magnesium L-threonate is not on the WADA Prohibited List is taken here from the source as of its stated date. The FDA does not review dietary supplements for safety and efficacy before they go on sale, as it does for drugs. Transparent labeling and independent quality testing therefore remain important.

Safety, side effects and interactions

Large long-term studies specifically on magnesium L-threonate are lacking. The safety assessment rests mostly on smaller, short studies, including one from 2016, a placebo-controlled study from 2024 and another from 2025. Broader experience with other magnesium salts provides context, but it does not replace specific long-term data. Source Source Source

Which side effects have been observed?

The most commonly described are loose stools and mild abdominal discomfort. The source article reports fewer gastrointestinal effects with threonate and glycinate than with oxide or citrate and suggests that a lower elemental amount, and therefore a weaker osmotic effect, may explain this. Occasional headaches and mild fatigue have been reported. In the human studies cited, no serious events were attributed to MgT; that does not prove a comprehensive safety profile. The US NIH set a tolerable upper intake level of 350 mg of elemental magnesium per day from supplements. Above that, the risk of gastrointestinal complaints in particular rises; in people at risk, hypermagnesemia can also occur. This is a US classification, not an individual dosing recommendation.

Drug interactions

• Bisphosphonates such as alendronate and risedronate: magnesium can bind them in the gut and markedly reduce their absorption and effectiveness. The source article cites a gap of at least 2 hours. The spacing actually needed must be clarified with a doctor or pharmacist for the specific medicine.

• Fluoroquinolones such as ciprofloxacin and levofloxacin: insoluble complexes with magnesium can impair absorption of the antibiotic and therefore treatment of the infection. The stated minimum of 2 hours should not be taken as a rule that suffices for every product; the dosing instructions for each medicine are what count.

• Tetracyclines such as doxycycline and minocycline: here too, complex formation can reduce absorption. The source article cites a gap of at least 2 hours; an individually suitable schedule should be worked out with a doctor or pharmacist.

• Diuretics: loop and thiazide diuretics increase magnesium excretion, while potassium-sparing drugs can reduce it. With long-term combination with magnesium supplements, checking the serum level may make sense.

• Other CNS-active supplements: MgT is often sold in combination products for cognition. Controlled human data on such interactions are lacking. Several centrally acting substances should not be combined without professional review.

Pregnancy, breastfeeding and organ function

Usual magnesium intake during pregnancy, within recommended amounts, is well described. For additional L-threonate, by contrast, controlled pregnancy data are lacking, so supplementation is usually avoided. The same applies to breastfeeding. With impaired kidney function, especially an eGFR below 60 mL/min/1.73 m², reduced excretion of magnesium can lead to hypermagnesemia. Clinical guidance is then needed before any magnesium supplementation. The source article names no specific liver concerns for the threonate component. Pediatric dosing has not been characterized; no studies in children are cited.

When is a closer check needed before starting?

The following situations call for particular caution. They are not a complete list of formal contraindications:

• Pregnancy and breastfeeding: no controlled human data on supplemental MgT doses.

• Impaired kidney function, given in the source article as eGFR <60: magnesium supplementation only after clinical assessment.

• Bisphosphonates, fluoroquinolones or tetracyclines without an agreed dosing schedule: the source article cites 2 hours, but the gap actually needed may differ.

• Diagnosed cognitive disorder: MgT must not replace a necessary workup or treatment.

• Diagnosed sleep disorder: sleep apnea and chronic insomnia need an appropriate workup. For insomnia, cognitive behavioral therapy for insomnia (CBT-I) is an important first-line treatment.

• Childhood: specific MgT doses have not been adequately studied.

In these situations, involve a health professional before starting, someone who knows your medications, conditions and relevant test results.

L-threonate, glycinate, citrate and oxide compared

The practical question is whether threonate’s targeted development rationale and the human evidence so far justify its higher price for your personal goal.

• Chemistry: L-threonate combines magnesium with two threonate components from vitamin C metabolism. Glycinate binds it to two glycine molecules. Citrate is the salt of citric acid; oxide is the simple oxide compound.

• Absorption: the source article compares L-threonate with other organic salts; its particular promise concerns delivery to the CNS. Glycinate and citrate are considered well-absorbed organic forms. For oxide, the source article gives about 4% absorption. Source

• Evidence focus: for L-threonate, the comparison overview cites a 2016 cognition study with N≈50 over 12 weeks and a 2024 sleep study with N≈80. The first figure is rounded relative to the 44 given earlier. For glycinate it lists subjective sleep and anxiety, for citrate general supplementation and laxative use, and for oxide mainly laxative use. These focus areas are not a verified ranking. Source Source

• Amounts studied or cited in the source article: L-threonate 1.5–2 g/day of Magtein, glycinate 200–400 mg elemental, citrate 200–400 mg elemental, oxide 250–500 mg elemental. These amounts are not interchangeable and are not a blanket dosing recommendation.

• Tolerability: with every form, larger amounts can cause gastrointestinal complaints. The source article describes fewer complaints with threonate and glycinate and stronger laxative effects with oxide and citrate. A clinical comparison at equal doses would need to be checked separately.

• Relative cost: L-threonate is placed as the most expensive form, glycinate in the middle, citrate and oxide cheaper.

• Regulation: the source article classifies all of them in the US as DSHEA dietary supplements and cites no FDA-authorized health claims. The exact scope of this blanket statement still needs checking.

For cognition and sleep, the marketing of L-threonate fits its development hypothesis. The human studies, however, are small and preliminary; the source article describes industry funding in the published RCTs. For general supply or a laxative effect, forms with a longer track record and a lower price are available. Serum and, where appropriate, red blood cell magnesium can look at one aspect of magnesium status, but they do not directly answer whether L-threonate works better for the brain. The salt form should therefore not be chosen on the basis of a blood value alone. Source

Which lab values can add information?

Serum magnesium is easy to obtain, but it reflects tissue and brain status only to a limited extent. An intracellular deficiency can occur despite a value within the reference range. The source article describes red blood cell magnesium as a longer-term cellular marker and suggests a baseline measurement plus a follow-up after 8–12 weeks. How informative this approach is for a given question has to be judged clinically; it does not measure brain magnesium. Source Source

• Serum magnesium shows the circulating concentration. The source article gives 0.85 mmol/L as a proposed updated lower limit and links it, based on review data, to a lower risk of dementia. That is confirmed here neither as a generally adopted lab standard nor as a proven prevention target. After 8–12 weeks, a moderate rise may be visible if overall intake has changed. Normal values do not reliably rule out low intracellular stores. Source

• Red blood cell magnesium: the source article describes it as a longer-term marker and more sensitive to chronic undersupply than serum. Whether it reliably reflects tissue status during supplementation needs its own clinical assessment. This value does not measure brain concentration either. Source

Baseline and follow-up measurements, where medically sensible, can add to a subjective assessment. They are not, however, a general prerequisite for interpreting every change in sleep or memory. Brain magnesium is not measured directly in routine clinical care. Serum and red blood cell values provide limited additional information and must not be taken as proof of a cognitive benefit.

When should memory or sleep problems be checked out?

Persistent cognitive complaints, declining memory, chronic insomnia or possible early neurological symptoms call for a medical assessment. The source article names a medical history, blood count, comprehensive metabolic panel, thyroid function, B12, vitamin D and depression screening as possible components. The selection depends on the individual question. For chronic insomnia or suspected sleep apnea, a targeted sleep medicine workup makes sense. Trying magnesium should not replace these steps.

Frequently asked questions

What is magnesium L-threonate?

It is a magnesium salt with threonate, a vitamin C metabolite; the brand form is called Magtein. Its development at MIT was based on the hypothesis of improved delivery to the brain. Human findings so far are preliminary and come in part from small, industry-funded studies on cognition and sleep. Compared with glycinate, citrate or oxide, what makes it distinctive is the development approach, not any established clinical superiority. Source

Does it help with cognition or sleep?

Limited study data report changes over 3–12 weeks. One study in older adults described cognitive differences after 12 weeks; a sleep study observed subjective changes over 3 weeks. These positive signals justify further research. So far, the evidence is not enough for an established treatment of cognitive or sleep disorders. Source Source

Which dose has been studied?

The figure given is 1.5–2 g/day of the Magtein formulation. The source article assigns roughly 144 mg of elemental magnesium per day to this range; more precisely, the main text ties that amount to the upper formulation dose. It was studied over 12 weeks in 50- to 70-year-olds with cognitive complaints, and a comparable formulation was studied in people with sleep complaints. Grams of the compound and milligrams of elemental magnesium must not be treated as the same thing. Source Source

Which side effects are known?

Mainly loose stools and abdominal discomfort have been reported. The source article describes lower rates than with some other magnesium salts, such as oxide or citrate; how solid those direct comparisons are remains to be checked. The 2024 sleep RCT documented, among other things, transient gastrointestinal complaints and mild headaches. The favorable tolerability picture so far is no substitute for comprehensive long-term data. Source Source

Is magnesium L-threonate FDA approved?

The source article cites no FDA approval for a medical indication. In the US it is sold as a dietary supplement under DSHEA; Magtein is attributed to Magceutics/AIDP. As of the stated date of May 2026, the source cites no FDA-authorized health claim related to cognition or sleep.

How does it compare with glycinate, citrate and oxide?

L-threonate was developed specifically around a hypothesis of delivery to the CNS. Glycinate is studied for sleep and anxiety complaints, citrate is used for general supply and as a laxative, and oxide has comparatively low oral bioavailability. Animal comparisons leave open whether threonate has a clear advantage in delivery to the brain. These different research focuses do not add up to a general ranking that applies to everyone. Source Source Source

Which drug interactions matter?

Magnesium can bind bisphosphonates, fluoroquinolones and tetracyclines in the gut and reduce their absorption. The source article cites a gap of at least 2 hours; the specific drug instructions and advice from a pharmacist or doctor are what count, since this gap is not enough for every product. Controlled safety data for MgT in pregnancy and breastfeeding are lacking, whereas usual magnesium intake from the diet is better described.

Which blood tests can be useful?

The source article suggests serum magnesium and red blood cell magnesium before starting, plus a follow-up after 8–12 weeks. It gives 0.85 mmol/L as a proposed lower serum limit. Whether tests are needed, and which reference range applies, depends on the clinical situation. Both markers have limits and cannot directly confirm brain magnesium or any treatment effect on cognition or sleep. Source Source Source

References

• Slutsky I, Abumaria N, Wu LJ, Huang C, Zhang L, Li B, Zhao X, Govindarajan A, Zhao MG, Zhuo M, Tonegawa S, Liu G (2010). Enhancement of learning and memory by elevating brain magnesium. Neuron, 65(2), 165-77. https://doi.org/10.1016/j.neuron.2009.12.026

• Sun Q, Weinger JG, Mao F, Liu G (2016). Regulation of structural and functional synapse density by L-threonate through modulation of intraneuronal magnesium concentration. Neuropharmacology, 108, 426-39. https://doi.org/10.1016/j.neuropharm.2016.05.006

• Liu G, Weinger JG, Lu ZL, Xue F, Sadeghpour S (2016). Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Alzheimer’s disease : JAD, 49(4), 971-90. https://doi.org/10.3233/JAD-150538

• Zhou H, Bi GQ, Liu G (2024). Intracellular magnesium optimizes transmission efficiency and plasticity of hippocampal synapses by reconfiguring their connectivity. Nature communications, 15(1), 3406. https://doi.org/10.1038/s41467-024-47571-3

• Li W, Yu J, Liu Y, Huang X, Abumaria N, Zhu Y, Huang X, Xiong W, Ren C, Liu XG, Chui D, Liu G (2014). Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer’s disease mouse model. Molecular brain, 7, 65. https://doi.org/10.1186/s13041-014-0065-y

• Akkaya EC, Ilgin R, Adil H, Çelik A (2025). Magnesium L-Threonate Reduces Hippocampal Amyloid-β Load without Cognitive Improvement in a PTU-induced Hypothyroidism Model in Young Rats. Molecular neurobiology, 63(1), 8. https://doi.org/10.1007/s12035-025-05322-5

• Uysal N, Kizildag S, Yuce Z, Guvendi G, Kandis S, Koc B, Karakilic A, Camsari UM, Ates M (2019). Timeline (Bioavailability) of Magnesium Compounds in Hours: Which Magnesium Compound Works Best?. Biological trace element research, 187(1), 128-136. https://doi.org/10.1007/s12011-018-1351-9

• Pardo MR, Garicano Vilar E, San Mauro Martín I, Camina Martín MA (2021). Bioavailability of magnesium food supplements: A systematic review. Nutrition (Burbank, Los Angeles County, Calif.), 89, 111294. https://doi.org/10.1016/j.nut.2021.111294

• Costello RB, Nielsen F (2017). Interpreting magnesium status to enhance clinical care: key indicators. Current opinion in clinical nutrition and metabolic care, 20(6), 504-511. https://doi.org/10.1097/MCO.0000000000000410

• Sitzia C, Sterlicchio M, Crapanzano C, Dozio E, Vianello E, Corsi Romanelli MM (2020). Intra-erythrocytes magnesium deficiency could reflect cognitive impairment status due to vascular disease: a pilot study. Journal of translational medicine, 18(1), 458. https://doi.org/10.1186/s12967-020-02645-w

• Zhu D, Su Y, Fu B, Xu H (2018). Magnesium Reduces Blood-Brain Barrier Permeability and Regulates Amyloid-β Transcytosis. Molecular neurobiology, 55(9), 7118-7131. https://doi.org/10.1007/s12035-018-0896-0

• Cazzaniga A, Fedele G, Castiglioni S, Maier JA (2022). The Presence of Blood-Brain Barrier Modulates the Response to Magnesium Salts in Human Brain Organoids. International journal of molecular sciences, 23(9). https://doi.org/10.3390/ijms23095133

• Lopresti AL, Smith SJ (2025). The effects of magnesium L-threonate (Magtein). Frontiers in nutrition, 12, 1729164. https://doi.org/10.3389/fnut.2025.1729164

• Hausenblas HA, Lynch T, Hooper S, Shrestha A, Rosendale D, Gu J (2024). Magnesium-L-threonate improves sleep quality and daytime functioning in adults with self-reported sleep problems: A randomized controlled trial. Sleep medicine: X, 8, 100121. https://doi.org/10.1016/j.sleepx.2024.100121

• Arab A, Rafie N, Amani R, Shirani F (2023). The Role of Magnesium in Sleep Health: a Systematic Review of Available Literature. Biological trace element research, 201(1), 121-128. https://doi.org/10.1007/s12011-022-03162-1

• Rawji A, Peltier MR, Mourtzanakis K, Awan S, Rana J, Pothen NJ, Afzal S (2024). Examining the Effects of Supplemental Magnesium on Self-Reported Anxiety and Sleep Quality: A Systematic Review. Cureus, 16(4), e59317. https://doi.org/10.7759/cureus.59317

• Huang Y, Huang X, Zhang L, Han F, Pang KL, Li X, Shen JY (2018). Magnesium boosts the memory restorative effect of environmental enrichment in Alzheimer’s disease mice. CNS neuroscience & therapeutics, 24(1), 70-79. https://doi.org/10.1111/cns.12775

• Xiong Y, Yang Y, Ruan Y, Ou W, Hu Z, Li W, Xiao N, Liao W, Liu J, Liu Z, Luo Q, Liu F, Liu J (2025). Magnesium-L-threonate Ameliorates Cognitive Deficit by Attenuating Adult Hippocampal Neurogenesis Impairment in a Mouse Model of Alzheimer’s Disease. Experimental neurobiology, 34(2), 53-62. https://doi.org/10.5607/en24030

• Fu C, Huang L, Lian C, Yue J, Lin P, Xu L, Lai W, Gao C, Li C, Long Y (2025). Effects of long-term magnesium L-threonate supplementation on neuroinflammation, demyelination and blood-brain barrier integrity in mice with neuromyelitis optica spectrum disorder. Brain research, 1846, 149234. https://doi.org/10.1016/j.brainres.2024.149234

• Rosanoff A, West C, Elin RJ, Micke O, Baniasadi S, Barbagallo M, Campbell E, Cheng FC, Costello RB, Gamboa-Gomez C, Guerrero-Romero F, Gletsu-Miller N, von Ehrlich B, Iotti S, Kahe K, Kim DJ, Kisters K, Kolisek M, Kraus A, … MaGNet Global Magnesium Project (MaGNet) (2022). Recommendation on an updated standardization of serum magnesium reference ranges. European journal of nutrition, 61(7), 3697-3706. https://doi.org/10.1007/s00394-022-02916-w

Provenance and editorial review status

Translated and prepared for Nutrient Desk from the source article. Promotional offers have been removed. Bibliographic details are kept in the original for unambiguous identification. Clinical review and publication sign-off are pending.